SCHEMBL5457902

SCHEMBL5457902

CCOc1ccc(C)cc1NC(=O)Nc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 1/20 0.53
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
POLB P06746 1/20 0.46
BLM P54132 1/20 0.46
RET P07949 2/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
PGK1 P00558 1/20 0.43
DGAT1 O75907 5/20 0.43
GPR119 Q8TDV5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462442 0.91 WNT3A (0.51) WNT3ADDB1CRBNMAPTSMN1; SMN2
SCHEMBL5469390 0.91 WNT3A (0.53) WNT3ADDB1CRBNMAPTSMN1; SMN2
SCHEMBL5465465 0.91 WNT3A (0.51) WNT3ADDB1CRBNMAPTSMN1; SMN2
SCHEMBL5453453 0.89 KMT2A (0.54) WNT3ADDB1CRBNMAPTSMN1; SMN2
SCHEMBL5456953 0.88 MAPT (0.51) MAPTSMN1; SMN2MEN1KMT2ATP53
SCHEMBL5458258 0.88 MAPT (0.53) MAPTSMN1; SMN2MEN1KMT2ATP53
SCHEMBL5451401 0.84 KMT2A (0.51) MAPTSMN1; SMN2MEN1KMT2ATP53
SCHEMBL5459726 0.82 WNT3A (0.51) WNT3ADDB1CRBNMAPTSMN1; SMN2
SCHEMBL5460864 0.82 WNT3A (0.54) WNT3ADDB1CRBNSMN1; SMN2LMNA
SCHEMBL5460059 0.82 MAPT (0.50) WNT3ADDB1CRBNMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 WNT3A 3010/4885DDB1 1256/4885CRBN 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.